Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;1(1):25-27.
doi: 10.1186/cvm-1-1-025.

Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

Peter Sleight  1
Affiliations

Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

Peter Sleight. Curr Control Trials Cardiovasc Med. 2000.

Abstract

Analysis of subgroup results in a clinical trial is surprisingly unreliable, even in a large trial. This is the result of a combination of reduced statistical power, increased variance and the play of chance. Reliance on such analyses is likely to be more erroneous, and hence harmful, than application of the overall proportional (or relative) result in the whole trial to the estimate of absolute risk in that subgroup. Plausible explanations can usually be found for effects that are, in reality, simply due to the play of chance. When clinicians believe such subgroup analyses, there is a real danger of harm to the individual patient.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. Oxford Textbook of Medicine, edn 3. Edited by Weatherall DJ, Ledingham JGG, Warrell DA. Oxford, UK: Oxford University Press, 1996. pp. 21–32.
    1. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. . Lancet. 1999;353:611–616. doi: 10.1016/S0140-6736(98)05012-0. - DOI - PubMed
    1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;ii:349–360. - PubMed
    1. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med. 2000;342:145–153. doi: 10.1056/NEJM200001203420301. - DOI - PubMed
    1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet . 1994;343:311–322. doi: 10.1016/S0140-6736(94)91161-4. - DOI - PubMed

LinkOut - more resources